Search results for "POINTS"

showing 10 items of 415 documents

Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…

2017

Lung cancer is rich in molecular complexities and driven by different abnormal molecular pathways. Personalised medicine has begun to bring new hope for the treatment of patients with lung cancer, especially non-small cell lung cancer (NSCLC). The development of molecularly targeted therapy (small molecules and monoclonal antibodies) has significantly improved outcomes in the metastatic setting for patients with NSCLC whose tumours harbour activated oncogenes such as epidermal growth factor receptor (EGFR) and translocated genes like anaplastic lymphoma kinase (ALK). In addition, immune checkpoint inhibitors have also dramatically changed the therapeutic landscape of NSCLC. In particular, m…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPembrolizumabNSCLCTargeted therapy03 medical and health sciences0302 clinical medicinePDL-1/PD-1AtezolizumabInternal medicineMedicineAnaplastic lymphoma kinase1506Epidermal growth factor receptorLung cancerbiologybusiness.industryImmunotherapymedicine.diseaseEditorial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologybiology.proteinImmune checkpointsImmune checkpointHuman medicineNivolumabbusinessImmune checkpoints; NSCLC; PDL-1/PD-1
researchProduct

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a…

2020

Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if soluble forms of the immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, and BTN2A1, could be candidate to predict the response to immune-checkpoint blockade therapy. We evaluated the plasma levels in a learning cohort of metastatic clear cell renal carcinoma (mccRCC) patients treated with the anti-PD-1 agent nivolumab by ad hoc developed ELISA’s. Using specific cut-offs determined…

0301 basic medicineOncologySettore MED/06 - Oncologia MedicaProgrammed Cell Death 1 ReceptorB7-H1 Antigen0302 clinical medicineRenal cell carcinomaPD-1Immunology and AllergyProspective Studiespredictive biomarkerRC254-282ComputingMilieux_MISCELLANEOUSOriginal ResearchbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensfood and beveragesBTN3A1PrognosisTreatment efficacyKidney Neoplasms3. Good healthNivolumabOncology030220 oncology & carcinogenesisBiomarker (medicine)[SDV.IMM]Life Sciences [q-bio]/Immunologysoluble immune-checkpointsNivolumabResearch ArticlePD-L1medicine.medical_specialtyrenal cell carcinomabutyrophilinImmunology03 medical and health sciencesAntigens CDInternal medicinePD-L1mental disordersmedicineHumansIn patientCarcinoma Renal Cellbutyrophilinsbusiness.industryCancercirculating immune checkpointsPlasma levelsRC581-607medicine.diseasecirculating immune checkpoint030104 developmental biologyBTN2A1immunotherapy responsebiology.proteinImmunologic diseases. Allergybusiness
researchProduct

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

2018

The eighth annual conference of “Innovative therapy, monoclonal antibodies, and beyond” was held in Milan on Jan. 26, 2018, and hosted by Fondazione IRCCS–Istituto Nazionale dei Tumori (Fondazione IRCCS INT). The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets, and ii) clinical translation, as well as a third session of presentations from young investigators, which focused on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies. Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor heterogeneity, with key topics addressing: 1) tumor heterogeneit…

0301 basic medicineOncologyTumor heterogeneitymedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunologyMonoclonal antibodyGeneral Biochemistry Genetics and Molecular BiologyTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyInternal medicineImmunology and AllergyMedicineAnimalbusiness.industryMicrobiotaRepertoireMelanomaImmune checkpoints inhibitionAntibodies MonoclonalImmunotherapymedicine.diseaseCancer metabolismGastrointestinal MicrobiomeRadiation therapy030104 developmental biologyCancer stemness signaling030220 oncology & carcinogenesisNeoplasmImmunotherapybusinessHumanCytokine & Growth Factor Reviews
researchProduct

Cytotoxicity ofSalvia miltiorrhizaAgainst Multidrug-Resistant Cancer Cells

2016

Salvia miltiorrhiza Bunge (Lamiaceae) is a well-known Chinese herb that possesses numerous therapeutic activities, including anticancer effects. In this study, the cytotoxicity and the biological mechanisms of S. miltiorrhiza (SM) root extract on diverse resistant and sensitive cancer cell lines were investigated. CEM/ADR5000 cells were 1.68-fold resistant to CCRF-CEM cells, while HCT116 (p53[Formula: see text] and U87.MG[Formula: see text]EGFR cells were hypersensitive (collateral sensitive) compared to their parental cells. SM root extract stimulated ROS generation, cell cycle S phase arrest and apoptosis. The induction of the intrinsic apoptotic pathway was validated by increased cleavag…

0301 basic medicinePoly ADP ribose polymerasep38 mitogen-activated protein kinasesApoptosisSalvia miltiorrhizaCaspase 3PharmacologyBiologySalvia miltiorrhiza03 medical and health sciences0302 clinical medicineCell Line TumorNeoplasmsHumansCytotoxicityCell Cycle CheckpointsGeneral MedicineCell cycleAntineoplastic Agents PhytogenicMolecular biology030104 developmental biologyComplementary and alternative medicineDrug Resistance NeoplasmApoptosisCaspases030220 oncology & carcinogenesisCancer cellReactive Oxygen SpeciesDrugs Chinese HerbalThe American Journal of Chinese Medicine
researchProduct

Dibutyltin(IV) and Tributyltin(IV) Derivatives of meso-Tetra(4 sulfonatophenyl)porphine Inhibit the Growth and the Migration of Human Melanoma Cells.

2019

Melanoma is the most aggressive and deadly form of skin cancer, which is largely due to its propensity to metastasize. Therefore, with the aim to inhibit the growth and the metastatic dissemination of melanoma cells and to provide a novel treatment option, we studied the effects of the melanoma treatment with two organotin(IV) complexes of the meso-tetra(4-sulfonato-phenyl)porphine, namely (Bu2Sn)2TPPS and (Bu3Sn)4TPPS. In particular, we showed that nanomolar concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS are sufficient to inhibit melanoma cell growth, to increase the expression of the full-length poly (ADP-ribose) polymerase (PARP-1), to induce the cell cycle arrest respectively at G2/M a…

0301 basic medicinePorphyrinsCellAntineoplastic AgentsApoptosisorganotin(IV)migrationArticleBRAF03 medical and health sciences0302 clinical medicineCyclin D1Cell MovementCell Line Tumormelanoma; organotin(IV); cellular growth; BRAF; cell cycle; migrationmedicinemelanomaHumansSTAT3Cell ProliferationDose-Response Relationship DrugMolecular StructurebiologyCell growthChemistryMelanomaCell migrationCell Cycle CheckpointsGeneral Medicinecellular growthCell cyclemedicine.disease030104 developmental biologymedicine.anatomical_structureFocal Adhesion Kinase 1030220 oncology & carcinogenesisbiology.proteinCancer researchcell cycleSkin cancerSignal Transduction
researchProduct

Sicilian Litchi Fruit Extracts Induce Autophagy versus Apoptosis Switch in Human Colon Cancer Cells

2018

Litchi chinensis Sonnerat is a tropical tree whose fruits contain significant amounts of bioactive polyphenols. Litchi cultivation has recently spread in Sicily where the climate conditions are particularly favorable for this crop. Recent findings have shown that Litchi extracts display anti-tumor and pro-apoptotic effects in vitro, but the precise underlying mechanisms have not been fully elucidated. In this study, we report for the first time the effects of Sicilian litchi fruit extracts on colon cancer cells. The results indicated that litchi exocarp, mesocarp and endocarp fractions reduce the viability and clonogenic growth of HT29 cells. These effects were due to cell cycle arrest in t…

0301 basic medicineProgrammed cell deathautophagyCell cycle checkpointAtg1Apoptosislcsh:TX341-641Litchi chinensisArticle03 medical and health sciencesHT29 Cells0302 clinical medicineLitchiSettore BIO/10 - BiochimicaHumansClonogenic assaySicilyNutrition and DieteticsPlant ExtractsChemistryKinaseAutophagyPolyphenolsLitchi chinensiCell Cycle CheckpointsAntineoplastic Agents PhytogenicCell biology030104 developmental biologycolon cancerApoptosisFruit030220 oncology & carcinogenesisColonic Neoplasmsanti-tumor activityCaco-2 Cells<i>Litchi chinensis</i>HT29 Cellslcsh:Nutrition. Foods and food supplyPhytotherapySignal TransductionFood ScienceNutrients
researchProduct

Whi7 is an unstable cell-cycle repressor of the Start transcriptional program

2017

Start is the main decision point in eukaryotic cell cycle in which cells commit to a new round of cell division. It involves the irreversible activation of a transcriptional program by G1 CDK-cyclin complexes through the inactivation of Start transcriptional repressors, Whi5 in yeast or Rb in mammals. Here we provide novel keys of how Whi7, a protein related at sequence level to Whi5, represses Start. Whi7 is an unstable protein, degraded by the SCFGrr1 ubiquitin-ligase, whose stability is cell cycle regulated by CDK1 phosphorylation. Importantly, Whi7 associates to G1/S gene promoters in late G1 acting as a repressor of SBF-dependent transcription. Our results demonstrate that Whi7 is a ge…

0301 basic medicineSaccharomyces cerevisiae ProteinsTranscription GeneticCell divisionScienceGeneral Physics and AstronomyRepressorSaccharomyces cerevisiaeBiologyArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesCyclinsGene Expression Regulation Fungallcsh:ScienceGeneticsRegulation of gene expressionCyclin-dependent kinase 1MultidisciplinaryYY1QPromoterCell Cycle CheckpointsGeneral ChemistryCell cycleRepressor Proteins030104 developmental biologyGATAD2Blcsh:QNature Communications
researchProduct

Cytotoxicity of seven naturally occurring phenolic compounds towards multi-factorial drug-resistant cancer cells

2016

Abstract Introduction In medical oncology, multi-drug resistance (MDR) of cancer cells continues to be a major impediment. We are in quest of novel anti-proliferative agents to overcome drug-resistant tumor cells. Methods In the present study, we investigated the cytotoxicity of 7 naturally occurring phenolic compounds including two isoflavonoids alpinumisoflavone ( 1 ) and laburnetin ( 2 ), one biflavonoid amentoflavone ( 3) , three lignans pycnanthulignene A ( 4 ), pycnanthulignene B ( 5 ), and syringaresinol ( 7 ) and one xanthone, euxanthone ( 6 ) against 9 drug-sensitive and MDR cancer cell lines. The resazurin reduction assay was used to evaluate the cytotoxicity of these compounds, w…

0301 basic medicineSyringaresinolPharmaceutical SciencePharmacologyAmentoflavone03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhenolsIsoflavonoidCell Line TumorNeoplasmsOxazinesDrug DiscoveryHumansCytotoxic T cellCytotoxicityMembrane Potential MitochondrialPharmacologyCell Cycle CheckpointsAlpinumisoflavoneAntineoplastic Agents PhytogenicDrug Resistance MultipleEnzyme Activation030104 developmental biologyXanthenesComplementary and alternative medicinechemistryDrug Resistance NeoplasmApoptosisCaspases030220 oncology & carcinogenesisCancer cellMolecular MedicineReactive Oxygen SpeciesPhytomedicine
researchProduct

Evaluation of viability PCR performance for assessing norovirus infectivity in fresh-cut vegetables and irrigation water

2016

Norovirus (NoV) detection in food and water is mainly carried out by quantitative RT-PCR (RT-qPCR). The inability to differentiate between infectious and inactivated viruses and the resulting overestimation of viral targets is considered a major disadvantage of RT-qPCR. Initially, conventional photoactivatable dyes (i.e. propidium monoazide, PMA and ethidium monoazide, EMA) and newly developed ones (i.e. PMAxx and PEMAX) were evaluated for the discrimination between infectious and thermally inactivated NoV genogroup I (GI) and II (GII) suspensions. Results showed that PMAxx was the best photoactivatable dye to assess NoV infectivity. This procedure was further optimized in artificially inoc…

0301 basic medicineVirus inactivation030106 microbiologyReal-Time Polymerase Chain Reactionmedicine.disease_causeMicrobiologyIrrigation waterMicrobiology03 medical and health sciencesstomatognathic systemPropidium monoazideVegetablesmedicineFood scienceInfectivityMicrobial ViabilitybiologyInoculationNorovirusGeneral Medicinebiology.organism_classification030104 developmental biologyFoodNorovirusRNA ViralVirus InactivationSpinachWater MicrobiologyHazard Analysis and Critical Control PointsFood ScienceEthidium monoazideInternational Journal of Food Microbiology
researchProduct

Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction

2020

Cisplatin, which induces DNA damage, is standard chemotherapy for advanced bladder cancer (BCa). However, efficacy is limited due to resistance development. Since artesunate (ART), a derivative of artemisinin originating from Traditional Chinese Medicine, has been shown to exhibit anti-tumor activity, and to inhibit DNA damage repair, the impact of artesunate on cisplatin-resistant BCa was evaluated. Cisplatin-sensitive (parental) and cisplatin-resistant BCa cells, RT4, RT112, T24, and TCCSup, were treated with ART (1&ndash

0301 basic medicineautophagyRMCell cycle checkpointDNA RepairDNA damageArtesunateCell Cycle ProteinsArticlegrowth inhibition03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineHumansddc:610Medicine Chinese Traditionalskin and connective tissue diseaseslcsh:QH301-705.5Cell ProliferationCisplatinartesunate (ART)Cell growthAutophagyapoptosisGeneral MedicineCell cycleG1 Phase Cell Cycle Checkpoints030104 developmental biologychemistrylcsh:Biology (General)Urinary Bladder NeoplasmsApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchbladder cancer (BCa)Growth inhibitioncisplatin resistanceMicrotubule-Associated Proteinsmedicine.drug
researchProduct